- Policy
- NA burdened as dispute continues despite Gov-KMA agreement
- by Lee, Jeong-Hwan Sep 8, 2020 06:11am
- As the dispute among medical community is deepening regardless of South Korea’s Ministry of Health and Welfare (MOHW) and Korean Medical Association (KMA) settling on an agreement, the National Assembly is now burdened with a grave responsibility to deliver the agreed terms and to fairly execute the medical reform plan. The Young Doct
- Policy
- There is no disadvantage in the long-term Rx due to COVID-19
- by Lee, Hye-Kyung Sep 8, 2020 06:11am
- It has been emphasized once again that there are no disadvantages for appropriate long-term prescriptions within the scope of medically recognized health authorities. It has been clarified that it will not cut down on necessary and appropriate long-term prescriptions so that medical institutions can actively respond to medical gaps due to doc
- Company
- The dismissal of an executive in Lundbeck Korea was unfair
- by An, Kyung-Jin Sep 8, 2020 06:11am
- The National Labor Relations Commission issued an order to reinstate the job, saying that the dismissal of former executives in Lundbeck Korea was unfair. According to related industries on the 7th, the National Labor Relations Commission held an interrogation meeting on July 30 and sided with Mr. A in the case of a ``unfair dismissal req
- Company
- The contradiction of generic exclusivity
- by Kim, Jin-Gu Sep 7, 2020 06:13am
- Let's imagine! This is the case when the rule for '1st place' in a marathon is set to be '14 seconds after the first goal scored'. Competition will become meaningless, and only fights will increase. The achievements of legitimate efforts that the first place should receive will be shared by numerous 'joint first prizes'. The controversy
- Company
- Court to rule against companies on eye drop pricing?
- by Chon, Seung-Hyun Sep 7, 2020 06:12am
- The end in two years of legal dispute over the eye drop pricing reduction seems to be approaching. The Supreme Court has ultimately ruled against pharmaceutical companies on one of the two pricing reduction litigation cases. And as the government has won both the first and second trials over the other case, it would be unlikely for the pharmaceu
- Policy
- SCD's Eylea biosimilar was approved for phase III trials
- by Lee, Tak-Sun Sep 7, 2020 06:12am
- SCD Pharm has been approved for a phase III clinical trial of a biosimilar for Eylea (Aflibercept, Bayer), a macular degeneration treatment for the third time in Korea. In June, it was approved for the third phase III clinical trial following Samsung Bioepis and Amgen. It is noted who will succeed in commercialization first in Korea. On th
- Company
- OTC pain reliever market grows surges, Tylenol up by 30%
- by Kim, Jin-Gu Sep 7, 2020 06:12am
- The OTC pain reliever market was yet again dominated by Tylenol and Geworin in the first half of this year. Compared to the first half of last year, specifically, Tylenol’s sales have surged 30 percent. Geworin, EZN6 and Tak-sen followed the market leader on the leader board and generated the highest six-month sales on the record. ◆
- InterView
- The corporation separation is started from Employee rights
- by Sep 7, 2020 06:12am
- Business divisions of large foreign pharmaceutical companies such as Pfizer and MSD are actively in progress. Pfizer separated the patent-expired drug business unit into Pfizer Upjohn last year, and MSD is working to spin off the women's health, patent-expired drug, and biosimilar business divisions into a new corporation called Organon &
- Company
- Hanmi·Chong Kun Dang, leading the erectile dysfunction tx
- by Chon, Seung-Hyun Sep 4, 2020 06:53am
- The growth of the domestic erectile dysfunction treatment market has slowed. In the aftermath of COVID-19, the market size has decreased from last year for the first or second consecutive quarter. Generics by Hanmi and Chong Kun Dang are leading the market. According to IQVIA, a drug research institute on the 3rd, the market for erectile dys
- Company
- Keytruda coverage expansion plan back to MSD for revision
- by Eo, Yun-Ho Sep 4, 2020 06:53am
- Regarding the Keytruda coverage expansion, the South Korean authority passed the ball back to MSD Korea. The pharmaceutical industry sources reported Health Insurance Review and Assessment Service (HIRA) informed MSD on Sept. 2 about PD-1 inhibitor Keytruda’s (pembrolizumab) financial burden reduction plan the Cancer Deliberation Commi
